title: Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
authors.forename: Narasimhan
authors.initials: N
authors.lastname: Ragavan
authors.forename: Paras B
authors.initials: PB
authors.lastname: Singh
authors.forename: Francis L
authors.initials: FL
authors.lastname: Martin
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Baird
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012307:Risk Factors
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen